Literature DB >> 14994398

Geographical and genetic factors do not account for significant differences in the clinical spectrum of giant cell arteritis in southern europe.

Miguel A Gonzalez-Gay1, Luigi Boiardi, Carlos Garcia-Porrua, Pierluigi Macchioni, Juan C Amor-Dorado, Carlo Salvarani.   

Abstract

OBJECTIVE: To investigate whether genetic and geographical differences may influence the clinical spectrum of giant cell arteritis (GCA), we compared the demographic and clinical features of patients with biopsy-proven GCA from Reggio Emilia (Northern Italy) and Lugo (Northwest Spain) during a 15-year period.
METHODS: We performed a retrospective review of the case records of all patients diagnosed with biopsy-proven GCA at Hospital Xeral-Calde (Lugo, Spain) and Hospital Santa Maria Nuova (Reggio Emilia, Italy) between 1 January 1986 and 31 December 2001. Both hospitals are the only referral centers for populations living in central Galicia and central Emilia Romagna, respectively.
RESULTS: During the period of study, 194 Lugo residents and 126 Reggio Emilia residents were diagnosed with biopsy proven GCA. Reggio Emilia patients were more likely to be female (74% vs 54%; p = 0.0001). Although Lugo patients complained of headache (86%) more commonly than did those from Reggio Emilia (77%), the difference was only marginally significant (p = 0.05). The proportion of patients with visual manifestations or visual loss was remarkably similar (22% for visual manifestations and 17% for visual loss in Lugo and 29% and 21% for Reggio Emilia residents). The mean erythrocyte sedimentation rate prior to the onset of therapy was also similar.
CONCLUSION: Apart from differences in sex, the clinical spectrum of GCA in these 2 Southern European regions was similar.

Entities:  

Mesh:

Year:  2004        PMID: 14994398

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  1 in total

1.  Epidemiology of giant cell arteritis in an Arab population: a 22-year study.

Authors:  Neil R Miller
Journal:  Br J Ophthalmol       Date:  2007-06       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.